Please assess the completion status of the following clinical trial:

Trial Title: [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years or greater.~* All patients or legal guardians are willing and able to sign written informed consent and HIPAA authorization in accordance with local and institutional guidelines.~* Enrolled on the FORESEE trial.~* Biopsy proven estrogen receptor positive breast cancer.~* Patient deemed refractory to all combinations of hormonal therapies by FORESEE trial investigators.~Exclusion Criteria:~* Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion.~* Patients who require monitored anesthesia for PET/CT scanning.~* Patients who are too claustrophobic to undergo PET/CT scanning.~* Patients who are pregnant or currently breast feeding.~* Any patient that is medically unstable defined as a patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at the time of imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment: all patients (Type: EXPERIMENTAL): One session of \[18F\]FES PET/CT Imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).